Cambridge Investment Research Advisors
LGND icon

Cambridge Investment Research Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Cambridge Investment Research Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$360K Buy
+1,139
New +$268K ﹤0.01% 3277
2021
Q2 		– Sell
-2,658
Closed -$253K – 3142
2021
Q1 		$253K Buy
+2,658
New +$251K ﹤0.01% 2418
2020
Q4 		– Sell
-4,320
Closed -$257K – 2753
2020
Q3 		$257K Buy
+4,320
New +$295K ﹤0.01% 2053
2019
Q2 		– Sell
-2,712
Closed -$213K – 2288
2019
Q1 		$213K Buy
2,712
+261
+11% +$19.8K ﹤0.01% 2030
2018
Q4 		$207K Sell
2,451
-167
-6% -$17.8K ﹤0.01% 1895
2018
Q3 		$448K Buy
2,618
+167
+7% +$25.2K ﹤0.01% 1512
2018
Q2 		$317K Sell
2,451
-80
-3% -$8.93K ﹤0.01% 1692
2018
Q1 		$261K Buy
+2,531
New +$250K ﹤0.01% 1774
2016
Q4 		– Sell
-9,443
Closed -$601K – 1772
2016
Q3 		$601K Buy
9,443
+1,758
+23% +$129K 0.01% 935
2016
Q2 		$572K Buy
+7,685
New +$570K 0.01% 875
2014
Q1 		– Sell
-9,459
Closed -$310K – 1325
2013
Q4 		$310K Buy
9,459
+311
+3% +$10.1K 0.01% 869
2013
Q3 		$247K Buy
+9,148
New +$257K 0.01% 944

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $637M AUM 40.98% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
IP
Isthmus Partners Madison, Wisconsin $1.03B AUM 22.86% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Cambridge Investment Research Advisors's LGND Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 1,139 shares worth $360K. The stake represents ﹤0.01% of the portfolio and ranks #3277 among its holdings. This is a return to the name: Cambridge Investment Research Advisors previously reported a position in LGND as recently as Q1 2021.

Cambridge Investment Research Advisors first reported a position in LGND in Q3 2013 and has held it in 12 quarters since. The position peaked at $601K in Q3 2016. 118 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Cambridge Investment Research Advisors held 1,139 shares of Ligand Pharmaceuticals worth $360K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Cambridge Investment Research Advisors position in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3277 holding.
  • Cambridge Investment Research Advisors first reported a position in Ligand Pharmaceuticals in Q3 2013 and has held it in 12 quarters since.
  • Cambridge Investment Research Advisors's Ligand Pharmaceuticals position peaked at $601K in Q3 2016.
  • 118 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.